

1

DISCLAIMER

This presentation contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

2

straumanngroup

2

AGENDA

Highlights	Guillaume Daniellot
Financials	Marcel Kellerhals
Recent achievements & strategy	Guillaume Daniellot
Outlook 2023	Guillaume Daniellot
Q&A	Guillaume Daniellot, Marcel Kellerhals

3

straumanngroup

3



4

SOLID HALF-YEAR RESULTS LIFTED BY SECOND QUARTER




⁵ ¹ Organic growth excluding FX and M&A effects ² Barring unforeseen events and excluding FX effects

straumanngroup

5

GREAT PERFORMANCE ACROSS ALL GEOGRAPHIES

ORGANIC REVENUE GROWTH IN THE SECOND QUARTER




⁶ * % of Group total revenue

6

CHINA: PENT-UP DEMAND DRIVING STRONG VOLUME GROWTH

COVID-19 EFFECT AND ACCELERATED ADOPTION OF VBP



7

7


GROWTH ACROSS ALL BUSINESSES

IMPLANTOLOGY KEPT ITS STRONG GROWTH PACE

Tooth replacement
and restoration



Tooth alignment



Digital Solutions




8

straumanngroup

8




9



10

CORE GROSS MARGIN AT 75.2%

IN %, ROUNDED




11

straumanngroup

11

CORE EBIT MARGIN AT 26%

IN %, ROUNDED




12

straumanngroup

12

POSITIVE DEVELOPMENT OF HALF-YEAR FREE CASH FLOW

IN CHF MILLION, ROUNDED



13

straumanngroup

13

HALF-YEAR CORE FINANCIALS AT A GLANCE

BUSINESS PERFORMANCE AND PRODUCTIVITY OFFSET CURRENCY HEADWINDS

In CHF million, rounded	HY1 2023	% of revenue	Margin change	Change in %	Comments
Revenue	1'217			9.1%	
COGS	-302	24.8%		8.4%	
GROSS PROFIT	915	75.2%	+20 bps		FX headwind -100 bps
Operating expenses	-598	49.1%		9.7%	
EBIT	317	26.0%	-10 bps		FX headwind -180 bps
Financial result	-36	3.0%		460.8%	
Associates	-5	0.4%		184.9%	
Income tax	-47	3.9%		-5.8%	
NET PROFIT	229	18.8%	-220 bps		FX headwind -190 bps
Basic EPS	1.43			-2.4%	

14

straumanngroup

14



RECENT ACHIEVEMENTS & STRATEGY

Guillaume Daniellot, CEO

15

straumanngroup

15

INNOVATION AND CAPACITY TO GROW MARKET SHARE IN PREMIUM IMPLANTOLOGY





Straumann BLT
Tapered standard



Straumann BLX
Bone Level for Immediacy



Straumann TLX
Tissue Level for Immediacy




straumanngroup

16

RENEWED PARTNERSHIP WITH ITI

STRATEGIC FOCUS ON EDUCATION WITH CONTINUOUS PARTNERSHIP FOR OVER 40 YEARS



17

straumanngroup

17

GEOGRAPHICAL EXPANSION DRIVES CHALLENGER IMPLANTOLOGY BRANDS

NEODENT

Anthogyr



Neodent ZI ceramic
implant solution



Anthogyr
Axiom X3



straumanngroup

18

GALVOSURGE ACQUISITION

ADRESSING THE MOST COMMON DISEASE IN PEOPLE WITH IMPLANTS: PERI-IMPLANTITIS

Peri-implantitis

- Soft tissue inflammation & bone loss
- Bacterial biofilm formation on implant surface



19

Unique solution



- To protect patients from implant loss
- Compatible with most dental implant systems
- Launch September 2023

straumanngroup

19

CLEARCORRECT FURTHER ENHANCES CLEARPILOT SOFTWARE

- Enhancing visualization and customization of posterior bite ramps
- Improving esthetics, optimized patient comfort and the effectiveness of the ramps
- Limited market release phase, full market release planned for the third quarter of 2023




20

straumanngroup

20

IMPROVING OUR VALUE PROPOSITION IN ORTHODONTICS

CUSTOMER AND PATIENT CENTRIC DIGITAL TRANSFORMATION




21

straumanngroup

21

UNIQUE CUSTOMER EXPERIENCE TO DRIVE GROWTH



22

straumanngroup

22

PERSONNEL CHANGES – YANG XU NEW GROUP CFO

- Chief Financial Officer and Member of the Executive Management Board to join end of August
- International experience in corporate finance, strategy, commercial and business development
- Master's degree in Management HEC Paris and MBA programs at London Business School and Stanford




straumanngroup

23

23

NET-ZERO TARGET INDEPENDENTLY APPROVED BY SBTi

CARING FOR THE PLANET BY REDUCING OUR EMISSIONS IN LINE WITH CLIMATE SCIENCE



2040 net-zero emissions
(scope 1, 2 and 3)

2030 - 42% scope 1 and 2
- 25% scope 3

24

straumanngroup

24



OUTLOOK 2023 CONFIRMED

Market environment and assumption

- Group believes global patient flow will remain stable
- Uncertain economic environments remain
- Outgrow the market

Revenue and profitability¹

- Group aims to achieve organic revenue growth in the high single-digit percentage range versus the prior year
- Profitability (core EBIT margin) expected around 25%, including growth investments

²⁶ ¹ Barring unforeseen circumstances



27

CALENDAR OF UPCOMING EVENTS

2023	Event	Location
30-31 August	Deutsche Bank North America Roadshow	Virtual
8 September	UBS Best of Switzerland Conference	Wolfsberg, Switzerland
12-13 September	Kepler Cheuvreux European Roadshow	Zurich, Barcelona
19-20 September	Mirabaud Canada Roadshow	Toronto, Montreal
31 October	Third-quarter results	
1-2 November	ZKB Equity Conference	Zurich
9 November	J.P. Morgan European Healthcare CEO Call Series	Virtual
15 November	CS Equity Forum Switzerland	Zurich
4 December	Berenberg European Conference	London


28

straumann group


28

CURRENCY EXPOSURE


Revenue breakdown H1 2023



Total cost breakdown H1 2023



Exchange rates development 2022 – Jun 2023



	Average exchange rates (rounded)			Closing	FX sensitivity (+/- 10%) on FY	
	2021	2022	Jun 2023	Jun 2023	Revenue	EBIT
1 EURCHF	1.080	1.004	0.988	0.976	+/- 36m	+/- 16m
1 USDCHF	0.911	0.950	0.916	0.900	+/- 33m	+/- 18m
1 BRLCHF	0.170	0.184	0.180	0.185	+/- 7m	+/- 1m
1 CNYCHF	0.141	0.141	0.131	0.124	+/- 9m	+/- 6m

straumanngroup

29

REPORTED FINANCIALS AT A GLANCE

In CHF million, rounded	H1 2023	% of revenue	Margin change	Change in %	Comments
Revenue	1'217			9.1%	
COGS	-302	24.8%		8.4%	
GROSS PROFIT	915	76.0%	+16 bps		FX headwind -96 bps
Operating expenses	-618	50.8%		12.4%	
EBIT	297	24.4%	-135 bps		FX headwind -177 bps
Financial result	-36	3.0%		460.8%	
Associates	-5	0.4%		184.9%	
Income tax	-49	2.7%		-1.9%	
NET PROFIT	206	16.9%	-371 bps		FX headwind -187 bps
Basic EPS	1.29			-10.8%	


30

straumanngroup

30

CORE NET PROFIT MARGIN REMAINS STABLE

IN CHF MILLION, ROUNDED



31

straumanngroup

31

CORE RESULTS RECONCILIATION

(in CHF 1 000)	IFRS	PPA amortization	Impairments	Restructuring	Other	CORE
Revenue	1 216 888					1 216 888
Cost of goods sold	(301 699)	65		63		(301 572)
Gross profit	915 189	65		63		915 316
Other income	3 873					3 873
Distribution expense	(217 504)	2 642				(214 862)
Administrative expense	(404 974)	1 566		15 825		(387 583)
Operating profit	296 584	4 273		15 888		316 745
Finance income	40 388					40 388
Finance expense	(76 850)					(76 850)
Share of result of associates	(4 629)					(4 629)
Profit before income tax	255 493	4 273		15 888		275 654
Income tax expense	(49 474)	(1 123)		3 596		(47 002)
NET PROFIT	206 019	3 150		19 484		228 653
Attributable to:						
Shareholders of the parent company	205 776	3 102		19 484		228 361
Non-controlling interests	243	48				292
Basic earnings per share (in CHF)	1.29					1.43
Diluted earnings per share (in CHF)	1.29					1.43
Operating profit	296 584	4 273		15 888		316 745
Depreciation & amortization	69 265	(4 273)		(6 003)		58 989
EBITDA	365 849			9 885		375 734

32

straumanngroup

32